Evidence map›Paper›PMID 35672237›Full record

ArticleTrends in immunology2022

Finding your niche: immune evasion in quiescent tumor reservoirs.

Trever T Greene, Katelynn R Kazane, Elina I Zuniga

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Trever T GreeneDivision of Biological Sciences, University of California, San Diego, CA 92093, USA.
Katelynn R KazaneDivision of Biological Sciences, University of California, San Diego, CA 92093, USA.
Elina I ZunigaDivision of Biological Sciences, University of California, San Diego, CA 92093, USA. Electronic address: eizuniga@ucsd.edu.

Funding

Pathways in Biological Sciences Training ProgramT32GM133351 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Matthew Daugherty, Randolph Y. Hampton · 2020 to 2026
$9.9M
Single-Cell Transcriptomic and Epigenetics CoreP01AI132122 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GOLDRATH, ANANDA W · 2018 to 2022
$9.8M
Inhibitory Pathways Underlying Viral Persistence In VivoR01AI081923 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Elina I Zuniga · 2009 to 2026
$6.6M
Positive Immune-regulators During Chronic Viral InfectionsR01AI113923 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZUNIGA, ELINA I · 2015 to 2024
$5.1M
Molecular Mechanisms Underlying Dendritic Cell Adaptations During Chronic InfectionR01AI145314 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZUNIGA, ELINA I · 2020 to 2024
$2.4M
NIAID NIH HHS P01 AI132122NIAID NIH HHS R01 AI081923NIAID NIH HHS R01 AI113923NIAID NIH HHS R01 AI145314NIGMS NIH HHS T32 GM133351
6 · The paper itself

Abstract

Emerging immunotherapies offer a new hope for cancer patients but are not always effective even when a tumor is recognized by the immune system. Baldominos and colleagues address this challenge by characterizing a resilient niche of metabolically unique quiescent cancer cells (QCCs) that resist T cell-mediated control.

Indexed as

Immune EvasionNeoplasmsHumansImmunotherapyT-LymphocytesTumor Microenvironment

Identifiers

PMID35672237
PMCPMC9674368

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.